High Purity Diethyl (hydroxymethyl)phosphonate for Antiviral Synthesis
Validating Diethyl (hydroxymethyl)phosphonate Purity ≥99.0% Against TCI America 97.0% GC Standards
In pharmaceutical process development, the purity profile of phosphonate esters directly influences downstream reaction efficiency. When evaluating Diethyl (hydroxymethyl)phosphonate, standard commercial grades often hover around 97.0% purity as seen in some catalog references. However, for robust antiviral intermediate synthesis, maintaining an assay of ≥99.0% is critical to minimize side reactions during phosphorylation steps.
Gas Chromatography (GC) remains the primary analytical method for validating this purity. Our internal quality control protocols utilize capillary GC with flame ionization detection to quantify the main peak area against known impurities. While lower purity grades may suffice for early-stage screening, scale-up requires tighter controls. The difference between 97.0% and 99.0% is not merely numerical; it represents a significant reduction in monoethyl ester residues and free phosphoric acid derivatives that can catalyze unwanted decomposition during heating cycles.
Validation protocols should include system suitability tests to ensure column resolution separates the hydroxymethyl group signal from potential ethyl degradation products. R&D teams must verify that the integration parameters account for tailing factors common in phosphonate analysis.
Technical Specifications for Sigma Aldrich 392626 Industrial Equivalent Antiviral Intermediate
Procurement managers often reference catalog number 392626 when specifying Hydroxymethylphosphonic acid diethyl ester for nucleotide analog production. Sourcing an industrial equivalent requires matching not only the CAS number (3084-40-0) but also the physical constants and impurity profiles associated with high-grade material. NINGBO INNO PHARMCHEM CO.,LTD. manufactures this chemical building block to meet or exceed these technical benchmarks while ensuring supply chain stability.
For engineers transitioning from laboratory-scale reagents to bulk production, consistency is key. The industrial equivalent must demonstrate consistent refractive index and density values across batches. Variations in these physical properties often indicate shifts in the esterification equilibrium during manufacturing, which can introduce hard-to-remove impurities.
We invite technical teams to review our specific product data via our Diethyl (hydroxymethyl)phosphonate product page for detailed alignment with your process requirements. Our production focuses on organic synthesis compatibility, ensuring the material integrates smoothly into existing phosphorylation workflows without requiring extensive re-validation of reaction parameters.
Critical COA Parameters and Impurity Thresholds for R&D Scale-Up
A Certificate of Analysis (COA) for antiviral intermediates must go beyond simple assay percentages. Critical parameters include water content, acidity, and specific organic impurities that affect catalyst life in subsequent steps. For Diethyl phosphonomethanol, trace water is a particular concern as it can hydrolyze the ester linkage under acidic or basic conditions used in nucleotide synthesis.
The following table outlines the typical technical parameters we monitor to ensure batch consistency suitable for scale-up:
| Parameter | Specification Limit | Typical Result | Test Method |
|---|---|---|---|
| Assay (GC) | ≥99.0% | 99.2% - 99.5% | GC-FID |
| Water Content | ≤0.5% | 0.1% - 0.3% | Karl Fischer |
| Acidity (as H3PO4) | ≤0.1% | 0.05% | Titration |
| Color (APHA) | ≤50 | 20 - 30 | Visual/Spec |
| Monoethyl Ester | ≤0.5% | 0.2% | GC-MS |
Please refer to the batch-specific COA for exact values upon request. Impurity thresholds for monoethyl esters are strictly controlled because these species can act as chain terminators or create separation challenges during purification of the final antiviral active pharmaceutical ingredient (API).
Impact of ≥99.0% Assay Grades on Antiviral Intermediate Synthesis Yields
The purity of the phosphonate starting material correlates directly with the overall yield of the antiviral intermediate. In multi-step synthesis routes, such as those used for tenofovir or similar nucleotide analogs, impurities carried over from the phosphonate stage can accumulate. A 99.0% assay grade reduces the burden on downstream purification columns and crystallization steps.
Higher purity minimizes the formation of side products during the coupling reaction. For process chemists, this means higher throughput and reduced solvent consumption for waste treatment. When impurity levels exceed 1.0%, the risk of forming colored by-products increases, which often requires additional activated carbon treatment or recrystallization cycles to meet cosmetic and purity specifications for the final drug substance.
Optimizing the input quality allows for tighter control over stoichiometry. Excess reagents are often used to drive reactions to completion, but if the starting phosphonate contains significant inactive mass, calculating the exact molar equivalents becomes difficult, leading to either wasted expensive reagents or incomplete conversion.
Bulk Packaging Integrity and Storage Protocols for Phosphonate Stability
Physical stability during logistics is as crucial as chemical purity. Diethyl (hydroxymethyl)phosphonate is typically shipped in 210L steel drums or IBC totes lined with compatible materials to prevent contamination. Proper sealing is essential to prevent moisture ingress, which can lead to hydrolysis during transit.
From a field experience perspective, we have observed that this chemical exhibits increased viscosity at temperatures below 10°C. In winter shipping scenarios, this viscosity shift can affect pumping rates during unloading at the receiving facility. Operators should ensure storage areas maintain a temperature above 15°C to maintain optimal flow characteristics for automated dosing systems. This is a non-standard parameter often omitted from basic safety data sheets but is critical for plant operations.
Storage protocols should mandate a dry, cool environment away from strong oxidizing agents. While we focus on physical packaging integrity and factual shipping methods to ensure product arrives in specification, customers should verify their local regulatory requirements for storage quantities. NINGBO INNO PHARMCHEM CO.,LTD. ensures all drums are sealed with tamper-evident closures to maintain integrity from the manufacturing line to your facility.
Frequently Asked Questions
What is the typical lead time for bulk orders of this phosphonate?
Standard lead times vary based on production schedules and inventory levels. Please contact our sales team for current availability and estimated shipping dates for your specific region.
Can you provide custom packaging for R&D quantities?
Yes, we offer various packaging options including smaller bottles for laboratory use and bulk drums for production. Custom packaging requests can be discussed during the quotation process.
What documentation is provided with each shipment?
Each shipment includes a batch-specific COA, SDS, and commercial invoice. Additional technical documentation can be provided upon request to support regulatory filings.
Is the material suitable for GMP manufacturing environments?
Our manufacturing processes are designed to support pharmaceutical supply chains. Please discuss your specific GMP requirements with our technical team to ensure alignment with your quality agreements.
Sourcing and Technical Support
Securing a reliable supply of high-purity phosphonates is essential for maintaining continuity in antiviral drug production. Our engineering team is available to discuss technical specifications, impurity profiles, and logistics requirements to support your R&D and manufacturing goals. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.